Americans spent an estimated $71.7 billion on GLP-1 drugs including Ozempic and Wegovy in 2023, a 500 percent increase from ...

Novo Nordisk (NYSE: NVO) has filed for U.S. approval of an oral version of its blockbuster weight loss drug Wegovy, the company confirmed to BioPharma Dive. The Danish drugmaker disclosed the ...

A daily pill developed by the US pharmaceutical company Lilly may become a convenient alternative to injectable drugs like ...

If you're starting a semaglutide GLP-1 RA medication like Wegovy or Ozempic for weight loss, you may be wondering how soon ...

Americans spent $71 billion on weight loss drugs in 2023 - as much as the country spent on foreign aid - Weight loss drugs ...

Prescribing of drugs between 2021 and 2023 shifted dramatically for both type 2 diabetes and weight loss for people with ...

Novo Nordisk argues Medicare should negotiate the price for six of its insulin products separately, though they contain the ...

Federal law allows compounding pharmacies to make copies of name brand drugs while there’s a supply shortage. But there's a ...

Novo Nordisk remains an industry leader, and currently offers both a 2.7% dividend yield and compelling value that can work ...

New research found hospital visits from Ozempic and Wegovy are rare, but can be serious. Experts explain the finding and ...

Novo Nordisk has awarded a 50 million kroner ($7.6M) grant to the University of Copenhagen to develop less processed ...